163 related articles for article (PubMed ID: 9205765)
1. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
Gedliczka O; Bobrzynski A; Rembiasz K; Fillat O; Torres J; Herrero E; Márquez M; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
[TBL] [Abstract][Full Text] [Related]
2. Ebrotidine versus ranitidine in the treatment of acute duodenal ulcer. A multicentre, randomized, double-blind, controlled clinical trial.
Matov V; Metchkov G; Krastev Z; Tchernev K; Mitova R; Márquez M; Torres J; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):555-9. PubMed ID: 9205764
[TBL] [Abstract][Full Text] [Related]
3. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
Tulassay Z; Döbrönte Z; Farkas I; Juhász L; Simon L; Prónai L; Torres J; Márquez M
Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ebrotidine and ranitidine combined with amoxicillin and metronidazole in the eradication of Helicobacter pylori in patients with duodenal ulcer.
Popiela T; Kulig J; Karcz D; Tabor J; Torres J; Márquez M; Fillat O; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):573-7. PubMed ID: 9205768
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
Puscas I; Puscas C; Coltau M; Pasca R; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
Gabryelewicz A; Czajkowski A; Skrodzka D; Marlicz K; Luca de Tena F; Aldeguer M; Chantar C; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ebrotidine compared with ranitidine in patients with duodenal ulcer.
Gabryelewicz A; Konturek SJ; Butruk E; Dzieniszewski J; Marlicz K; Nowak A; Torres J; Marquez M; Ortiz JA
Eur J Gastroenterol Hepatol; 1995 Apr; 7(4):361-6. PubMed ID: 7600143
[TBL] [Abstract][Full Text] [Related]
8. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
9. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
10. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
Muñoz-Navas M; Honorato J; Reina-Ariño M; Márquez M; Herrero E; Villamayor F; Torres J; Roset PN; Fíllat O; Camps F; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
[TBL] [Abstract][Full Text] [Related]
11. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
12. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T; Majka J; Konturek SJ
Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
[TBL] [Abstract][Full Text] [Related]
13. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
14. Double-blind crossover study of ranitidine and ebrotidine in gastro-esophageal reflux disease.
Sito E; Thor PJ; M[aczka M; Lorens K; Konturek SJ; Maj A
J Physiol Pharmacol; 1993 Sep; 44(3):259-72. PubMed ID: 8241527
[TBL] [Abstract][Full Text] [Related]
15. Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine.
Arroyo MT; Lanas A; Sáinz R
Eur J Gastroenterol Hepatol; 2000 Mar; 12(3):313-8. PubMed ID: 10750652
[TBL] [Abstract][Full Text] [Related]
16. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
Kuipers EJ; Hazenberg HJ; Quik RF; Hazenberg BP; de Zwart PA
Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
[TBL] [Abstract][Full Text] [Related]
18. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
19. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
20. Subacute toxicity of ebrotidine in rats and dogs.
Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):492-7. PubMed ID: 9205751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
